Massivemarkets

SEC Form 4

Keros Therapeutics, Inc. (KROS) insider trading

In the 12 months to Nov 20, 2026, 5 KROS insiders reported open-market sales of $113.5K across 8 filings; one director bought $75.8K.

Latest filing · Last 12 months · Source: SEC EDGAR · How we count

Open-market sales
$113.5K
8 filings · 5 insiders
Open-market purchases
$75.8K
6 filings · Jean Jacques Bienaime, Director
Pre-arranged sales (10b5-1)
8 of 8
All $113.5K sold was pre-arranged

Who traded KROS, and when

  • Purchase
  • Sale
  • Sale, pre-arranged (10b5-1)

KROS daily close from Nov 20, 2025 to Nov 20, 2026, between $9.17 and $21.84, last $11.06. 8 sale and 6 purchase filings by 6 insiders, marked at their filing dates. Jean Jacques Bienaime, Director: bought $75.8K across 6 filings, first filed Mar 11, 2026, last Aug 19, 2026. Julius Knowles, Director: sold $28.2K across 1 filing, first filed Jun 8, 2026, last Jun 8, 2026. Nima Farzan, Director: sold $28.2K across 1 filing, first filed Jun 8, 2026, last Jun 8, 2026. Alpna Seth, Director: sold $28.1K across 1 filing, first filed Jun 5, 2026, last Jun 5, 2026. Charles W. Newton, Director: sold $17.2K across 3 filings, first filed Jun 15, 2026, last Nov 19, 2026. Anne Prener, Director: sold $11.8K across 2 filings, first filed Nov 16, 2026, last Nov 19, 2026.

Largest mark · tap a row for others

Julius Knowles · Director

Sale $28,166

2,625 shares at $10.73 avg

Filed Jun 8, 2026 · traded Jun 4

Pre-arranged (10b5-1) · close on filing date $10.00

KROS daily closelast $11.06

Jean Jacques Bienaime · Director

$75.8K bought

Julius Knowles · Director

$28.2K sold

Nima Farzan · Director

$28.2K sold

Alpna Seth · Director

$28.1K sold

Charles W. Newton · Director

$17.2K sold

Anne Prener · Director

$11.8K sold
One row per insider; marks sit at the SEC filing date, sized by dollar value.

Open-market trades

14 filings in the last 12 months
Other insider activity (not market trades) · 21 records
  • Option exercises1 record
  • Tax withholding (sold to cover)7 records
  • Grants and awards7 records
  • Other6 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

How to read this page

Open-market purchase or sale
A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
Pre-arranged (10b5-1)
The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
Filing date
Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

Frequently asked questions

Has Keros Therapeutics, Inc.'s CEO sold stock?

No. Jasbir Seehra (CEO) made no open-market sales filed as CEO in the last 12 months.

How current is KROS’s insider data?

These are KROS Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

Build with AI

Track KROS insider trades with your agent

This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:

Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for KROS every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.